Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PTC299 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | PTC299 with an aromatase inhibitor |
| Name | Type | Description |
|---|---|---|
| PTC299 | DRUG | PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®) |
Major Eligibility Criteria: 1. Female sex. 2. Age ≥18 years. 3. Body weight 40-100 kg. 4. ECOG performance status of 0 or 1. 5. Histologically or cytologically confirmed adenocarcinoma of the breast. 6. Presence of metastatic disease not amenable to surgery, radiation therapy, or chemoradiotherapy ...
Top 20 of 87 competitors
PTC299 is an investigational small molecule being studied for the treatment of metastatic breast cancer. It was evaluated in a Phase 1 clinical trial in combination with a hormonal agent. The study enrolled 33 female patients aged 18 years and older in the United States.
PTC299 is being developed by PTC Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol PTCT. The company conducted a Phase 1 clinical trial of PTC299 for metastatic breast cancer.
PTC299 is in Phase 1 clinical development. It has completed one Phase 1 trial for metastatic breast cancer. PTC299 is investigational and has not been approved by the FDA, as it remains in early-stage clinical development.
PTC299 has been studied in one completed clinical trial, NCT00508586, titled "PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer." This Phase 1 study enrolled 33 female participants with metastatic breast cancer in the United States.
PTC299 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial for metastatic breast cancer. The drug remains in clinical development and has not received regulatory approval for any indication.